A modified regimen of pegylated liposomal doxorubicin, bortezomib, and dexamethasone is effective and well tolerated in the treatment of relapsed or refractory multiple myeloma

Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib

(2009) Raman Sood et al.   AMERICAN JOURNAL OF HEMATOLOGY

Cancer Statistics, 2009

(2009) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Phase II Trial of Combination Therapy With Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Myeloma

(2009) Andrzej J. Jakubowiak et al.   JOURNAL OF CLINICAL ONCOLOGY

Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial

(2009) C B Reeder et al.   LEUKEMIA

Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma

(2008) A. Palumbo et al.   ANNALS OF ONCOLOGY

Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

(2008) Jesús F. San Miguel et al.   NEW ENGLAND JOURNAL OF MEDICINE